Researchers at Mass General Brigham found that artificial intelligence software like ChatGPT could help speed up the screening process to find patients eligible for clinical trials—though they cautioned that additional safeguards would be necessary.

After a full data analysis, Altimmune is heralding phase 2 obesity data for pemvidutide as “best-in-class” for spurring weight loss while preserving lean mass.

Two scientists whose work sparked industry excitement about the prospect of using chimeric antigen receptor T cell (CAR-T) therapy for autoimmune disease are the recipients of the Lupus Research Alliance’s annual prize for scientific discoveries.

It’s been nearly three months since the U.S. government announced an outbreak of the bird flu virus on dairy farms. The World Health Organization considers the virus a public health concern because of its potential to cause a pandemic, yet the U.S. has tested only about 45 people across the country.

The digital health developer Evidation plans to expand its symptom-logging platform into migraine headaches with the goal of better illustrating their impacts on a person’s daily life.

Jazz Pharmaceuticals hit a bum note Thursday, reporting the failure of a phase 2b essential tremor trial to meet its primary endpoint. But the drugmaker saw numeric improvements and is waiting on the data from another study rather than immediately bringing the curtain down on the program.

Need to order supplies, track samples or get protocol-specific support for your clinical trial in the wee hours of the morning? Labcorp is offering a software package for investigator sites that it claims can do all this and more.

Taysha Gene Therapies has unfurled more data in the developmental disorder Rett syndrome, linking its gene therapy to improvements in the first adults and children to receive low doses of the candidate.

Marea Therapeutics has emerged with $190 million, a mid-stage clinical program and a plan to harness genetics and pioneer “the next frontier” of cardiometabolic medicines.

The FDA has placed three trials of Zentalis’ WEE1 candidate on partial hold in the wake of two deaths that are presumed to be from sepsis.